Adstiladrin: Uses, Dosage, Side Effects & Warnings - Drugs.com
Dec 9, 2024 · Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer. …
Bladder Cancer Treatment Options
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non …
Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN ...
May 6, 2024 · ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high …
FDA Approval Summary: Nadofaragene Firadenovec-vncg for …
Apr 1, 2025 · Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of …
ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in …
Adstiladrin (Nadofaragene Firadenovec-Vncg) for bladder cancer
Adstiladrin is also called nadofaragene firadenovec-vncg. Adstiladrin is a gene therapy that uses a non-replicating adenoviral vector (a modified virus that cannot multiply) to deliver a gene to …
Anyone treated with Adstiladrin for BCG-unresponsive bladder cancer?
Jul 22, 2024 · As you likely know, Adstiladrin (nadofaragene firadenovec-vncg) was recently approved for bladder cancer. It is a gene therapy currently used for adult patients with high …
NMIBC treatment success: Why less frequent dosing and …
Dec 15, 2025 · An example of this treatment advancement is nadofaragene firadenovec-vncg (Adstiladrin),a novel intravesical gene therapy for adults with BCG-unresponsive NMIBC with …
Nadofaragene Firadenovec for High-risk Non–Muscle Invasive Bladder Cancer
Jan 13, 2023 · The FDA has approved Adstiladrin (nadofaragene firadenovec-vncg) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle …
Adstiladrin for Bladder Cancer: Treatment & Benefits
Adstiladrin (nadofaragene firadenovec-vncg) is an FDA-approved gene therapy designed for high-risk BCG-unresponsive NMIBC. It represents a groundbreaking advancement in the treatment …